The reasonable application of nalbuphine in the sedation of painless gastroscopy

Effect of low dose nalbuphine combined with propofol for sedation on gastroscopy: a randomized, double-blind, controlled trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000032583

Enrollment

Unknown

Registered

2020-05-03

Start date

2020-05-01

Completion date

Unknown

Last updated

2020-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Early cancer screening

Interventions

experimental group:Nalbuphine combined with propofol

control group:normal saline

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. ASA I, II subjects aged 18-65 years; 2. Subjects undergoing gastroscopy under deep sedation; 3. Subjects willing to sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Subjects who are allergic to the study drug; 2. Subjects with sleep apnea syndrome; 3. Patients with serious cardiopulmonary, hepatorenal diseases; 4. Patients with upper respiratory tract infection; 5. Patients with a history of psychoactive drug abuse; 6. Subjects with body mass index (BMI) >=30kg / m2.

Design outcomes

Primary

Measure	Time frame
blood pressure;heartreat;Blood oxygen saturation;Respiratory rate;Body movement frequency and classification;Cough frequency and grade;	—

Countries

China

Contacts

Public ContactZhang Tianwei

The First Affiliated Hospital of Xiamen University

stone1550@sohu.com+86 592-2139590

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026